Navidea Biopharma

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, OH, June  15, 2020  (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce full enrollment in its ongoing NAV3-31 Phase 2B study titled “Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc99m Tilmanocept Planar Imaging”. All of the subjects have been enrolled in the three-arm trial, and the study is on track for the last patient to be screened, and evaluated by end of 2020. 

Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)

  Live Video Moderated Discussion with CEO, Jed Latkin, to be Held on Tuesday, June 16th, at 2:00 PM ET, Immediately Followed by an Interactive Q&A Session

Navidea Biopharmaceuticals to Present at the Virtual Investor Fireside Chat Series

Blink Charging

Liquidia Technologies Inc

Savara

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts for you to hedge out or bet with your portfolio today.

Top Stocks To Short With VIX Rallying

DUBLIN, Ohio, June  03, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results from the Company’s first interim analysis of its ongoing NAV3-31 phase 2b clinical study will be presented as a poster at the European League Against Rheumatism (“EULAR”) Congress 2020. The poster is titled, “A Phase 2b Study of Intravenously Administered Tc 99m Tilmanocept to Determine Differential Uptake, Reproducibility Over Time and Image Stability in Healthy Subjects and in Patients with Rheumatoid Arthritis (“RA”) on Stable Treatment.” 

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress

Navidea Biopharmaceuticals Inc. (NYSE: NAVB) shares more than doubled to close out the week after the company provided an update from its midstage study in patients with active rheumatoid arthritis (RA).

Why This Rheumatoid Arthritis Study Is Huge for Navidea Biopharma

Shares of Navidea Biopharmaceuticals Inc. NAVB, -1.55% more than doubled in very active premarket trading Friday, after the company provided upbeat data on an ongoing phase 2 trial of its treatment for rheumatoid arthritis.

Navidea Biopharmaceuticals stock rockets toward 13-month high on heavy volume after update trial data

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2020 Results - Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2019 Results - Earnings Call Transcript

Navidea Biopharmaceuticals' (NAVB) CEO Jed Latkin on Q3 2019 Results - Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2019 Results - Earnings Call Transcript

For real-time updates on NAVB, beat the news and login or try Benzinga Pro. Biotechnology company that specializes in precision medicine, Navidea Biopharmaceuticals Inc (NYSE: NAVB) today had a large opening gap of 23.84%.

What Caused The Opening Gap In Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NAVB) CEO Jed Latkin on Q1 2019 Results - Earnings Call Transcript

News for Navidea Biopharma Stock (NAVB)